Understanding Optimal Use and Interpretation of Assays in HCV This program is supported by educational grants from Understanding the Optimal Use and Interpretation of Assays…

1. 18 Dicembre 2012Inibitori delle proteasi di HCVdi I generazione: sono una reale innovazione?Antonio CraxìGastroenterologia & Epatologia,Di.Bi.M.I.S. Università di…

Challenges in managing hepatitis C virus infection Challenges in managing hepatitis C virus infection Ahmed Alwassief MD Current situation FDA Approval of HCV Treatments…

Slide 1Recent HCV treatment developments: In pursuit of perfectovir Professor Greg Dore Kirby Institute, UNSW Australia; & St Vincent’s Hospital, Sydney Slide 2 201320112015201220162014…

Hepatic Decompensations Agenda Hepatic decompensations Hepatic encephalopathy Treatment/precipitating factors SBP Differentiate from secondary peritonitis Variceal bleeding…

PowerPoint Presentation New Treatment for HCV G4 Towards an End to HCV Epidemic in Egypt Now let us move on to talk about the epidemiology of hepatitis C. 1. Rehman S, et…

UHN Liver Centre A case study: Hepatitis C treatment and severe anemia Colina Yim RN(EC), MN Nurse Practitioner CAHN 2013 TWH LIVER CENTRE UHN centre of excellence Objective…

AASLD 2010 HCV Feedback October 29 - November 2, 2010 Boston, Massachusetts Dr Allister J Grant Consultant Hepatologist Leicester Liver Unit Boceprevir, a potent inhibitor…

AASLD 2010 HCV Feedback October 29 - November 2, 2010 Boston, Massachusetts Dr Allister J Grant Consultant Hepatologist Leicester Liver Unit Boceprevir, a potent inhibitor…

Slide 1 Susanna Naggie, MD Assistant Professor of Medicine Duke Clinical Research Institute Durham, NC Investigational Agents for HCV: I Thought This Was Going To Get Easier…